Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
National Health Research Institutes PADI4 compound 7
- Development stage
- Preclinical
- Lead developer
- National Health Research Institutes
01
Overview
National Health Research Institutes PADI4 compound 7: sourced facts only. name: "In vitro, our derivatives were proved capable of potently inhibiting PADI4 and diminishing cellular citrullination; in vivo, the representative compound 7, 6,8-dimethoxy-1',3',3'-trimethylspiro[chromene-2,2'-indoline], effectively ameliorated the severity and pathologic progress of collagen type II antibody/LPS induced rheumatoid arthritis in a mouse model." [PMID:40714618]; target: "In vitro, our derivatives were proved capable of potently inhibiting PADI4 and diminishing cellular citrullination; in vivo, the representative compound 7, 6,8-dimethoxy-1',3',3'-trimethylspiro[chromene-2,2'-indoline], effectively ameliorated the severity and pathologic progress of collagen type II antibody/LPS induced rheumatoid arthritis in a mouse model." [PMID:40714618]; developer: "Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan, ROC." [PMID:40714618]; stage: "in vivo, the representative compound 7, 6,8-dimethoxy-1',3',3'-trimethylspiro[chromene-2,2'-indoline], effectively ameliorated the severity and pathologic progress of collagen type II antibody/LPS induced rheumatoid arthritis in a mouse model." [PMID:40714618]
02
Targets
PADI4 (Peptidyl arginine deiminase 4)
Beyond the preview
Go deeper on National Health Research Institutes PADI4 compound 7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on National Health Research Institutes PADI4 compound 7.